|
Match
|
Document |
Document Title |
|
|
7618956 |
Reduction of hair growth
Mammalian hair growth is reduced by applying an agonist of farnesoid X receptor.
|
|
|
7605152 |
17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
Compounds of structural formula I as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as...
|
|
|
7601708 |
Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
This invention is directed to methods for providing sustained systemic concentrations of therapeutic or prophylactic agents such as GABA analogs following oral administration to animals. This...
|
|
|
7601706 |
Bile-acid conjugates providing for sustained systemic concentration of drugs
This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed...
|
|
|
7598235 |
Bile-acid conjugates for providing sustained systemic concentrations of drugs
This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed...
|
|
|
7598234 |
Steroid derived antibiotics
A series of novel steroid derivatives are described. The steroid derivatives are antibacterial agents. The steroid derivatives also act to sensitize bacteria to other antibiotics including...
|
|
|
7572779 |
Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
A pharmaceutical dosage unit for oral administration to a human female comprising a therapeutically effective amount of 17β-estradiol-3-lower alkanoate, most preferably 17β-estradiol-3-acetate,...
|
|
|
7553830 |
Compositions for the delivery of negatively charged molecules
This invention features permeability enhancer molecules, and methods, to increase membrane permeability of various molecules, such as nucleic acids, polynucleotides, oligonucleotides, enzymatic...
|
|
|
7553829 |
Treatment of chronic fatigue syndrome and fibromyalgia syndrome
Chronic fatigue syndrome (CFS) and fibromyalgia syndrome (FMS) can be treated by the administration of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof.
|
|
|
7550452 |
Cationic lipids and use thereof
The present invention relates to cationic lipids, methods for preparing some and methods for effectively transporting anionic molecular substances into cell by using said cationic lipids. The...
|
|
|
7544673 |
Coating compositions for bioactive agents
A coating composition and related method for use in applying a bioactive agent to a surface in a manner that will permit the bioactive agent to be released from the coating in vivo. The composition...
|
|
|
7538100 |
17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
The invention relates to 17α-alkyl-17β-oxy-estra-1,3,5(10)-trienes that have an antiestrogenic action with general formula I. In addition, the invention also relates to...
|
|
|
7534780 |
Estradiol prodrugs
The invention relates to estradiol prodrugs of general formula (I), in which group Z is bonded to the steroid,
process for their production, pharmaceutical compositions that contain these...
|
|
|
7528123 |
Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11
Disclosed is a novel class of steroid compounds based on estradiol, and carrying an 11β-substitution. Said substitution is a hydrocarbon group which may be linear or branched, provided that it...
|
|
|
7524836 |
Nitrooxyderivative steroidal compounds
Steroidal compounds or their salts having general formulas (I) and (II) wherein: s is an integer equal to 1 or 2, preferably s=2; b0=0 or 1; A=R—, wherein R is the steroidal drug radical, C and C...
|
|
|
7524835 |
Tetrol steroids and esters
The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition...
|
|
|
7521068 |
Dry powder aerosols of nanoparticulate drugs
There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the...
|
|
|
7514472 |
Fat or oil composition
Described is a fat or oil composition which comprises at least 35 wt % of a diacylglycerol, the constituent fatty acids of said diacylglycerol satisfying the following equation: (an amount of a...
|
|
|
7514420 |
Steroids having 1,8-unsaturation and formulations comprising same
The instant invention provides potent antiandrogen compounds, such as 3β-acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1,5-diene-17-ethylene ketal, and methods for their use in...
|
|
|
7507725 |
Compounds with sulphonamide group and pharmaceutical compositions containing these compounds
The invention relates to compounds which, acting as a prodrug and/or support, enable an active agent to be taken up by the erythrocytes and/or an active agent to bind to the erythrocytes. The...
|
|
|
7501409 |
Preparations for oral administration
The present invention provides a preparation for oral administration containing a medicinal substance having cGMP-specific phosphodiesterase inhibitory activity and showing decrease of solubility...
|
|
|
7501403 |
Bile acid or bile salt fatty acid conjugates
The present invention relates to the use of a bile acid or bile salt fatty acid conjugate of general formula II
W-X-G
|
|
|
7498322 |
Antiangiogenic agents
Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae:
wherein R a ...
|
|
|
7494680 |
Fat or oil composition
Provided is a fat or oil composition containing the following components (A), (B) and (C): (A) 100 parts by weight of a fat or oil containing from 0.1 to 10 wt. % of a monoglycerol monofatty acid...
|
|
|
7473687 |
Methods for the treatment of a traumatic central nervous system injury
Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a...
|
|
|
7459445 |
Estrogenic compounds and topical pharmaceutical formulations of the same
Novel estrogenic compounds of Formula I are provided.
wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R 1 is...
|
|
|
7456161 |
Use of DHEA and DHEA-sulfate for the treatment of chronic obstructive pulmonary disease
A method for treating or preventing chronic obstructive pulmonary disease (COPD) by using as active agent a non-glucorticoid steroid, analogue thereof, such as dehydroepiandrosterone (DHEA) and...
|
|
|
7427610 |
2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action
Disclosed are compounds of formula I
and use thereof in a method of treating a tumor disease that can be influenced positively by the inhibition of tubulin polymerization.
|
|
|
7419972 |
2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
The invention relates to new 2-substituted estra-1,3,5(10)-trien-17-ones of formula I
as well as their pharmaceutically acceptable salts, their methods of manufacture and use as medicaments for...
|
|
|
7414043 |
9-α-substituted estratrienes as selectively active estrogens
This invention describes the new 9α-substituted estratrienes of general formula I
in which R 3 , R 7 , R 7′ , R 13 , R 16 as well as R 17 and R 17′ have the meanings that are indicated...
|
|
|
7410959 |
Therapeutic uses for aminosterol compounds
A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically...
|
|
|
7387786 |
Food additive compositions containing sterol esters, solubilizing agents, dispersants and antioxidants
A food additive useful for lowering serum cholesterol in humans contains a sterol or stanol ester of a fatty acid or a dicarboxylic acid ester of a sterol or stanol made by reacting a sterol,...
|
|
|
7384926 |
Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma
The invention provides pharmaceutical compositions containing non-feminizing estrogen and methods of using these compositions to prevent or ameliorate retinal and optic nerve damage associated with...
|
|
|
7381416 |
Selenohydroxy acids and their derivatives, applications in nutrition, cosmetics and pharmaceutics
The purpose of this invention is:
new selenohydroxy acid compounds and their derivatives; their process for the preparation; use of the new compounds as precursors of L(+)-selenomethionine...
|
|
|
7378406 |
Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
The present invention relates to methods and uses for preventing or treating hormone-dependent disease, in particular breast cancer, in a mammal by antiprogestins, in particular antiprogestin...
|
|
|
7378404 |
8β-hydrocarbyl-substituted estratrienes for use as selective estrogens
This invention describes the new 8β-substituted estratrienes of general formula I in which R 2 , R 3 , R 6 , R 6′ , R 7 , R 7′ , R 9 , R 11 , R 11′ , R 12 , R 14 , R 15 , R 15′ , R 16 , R...
|
|
|
7375098 |
8β-vinyl-11β-(ω-substituted)alkyl-estra-1,3,5(10)-trienes
This invention relates to 8β-vinyl-11β-(ω-substituted)alkyl-estra-1,3,5(10)-trienes
of general formula I
with ERβ-antagonistic activity, process for their production, their intermediate...
|
|
|
7371741 |
Estradiol derivatives and pharmaceutical compositions using same
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula:
wherein the variables are defined in the...
|
|
|
7351699 |
Use of DHEA or precursors or metabolic derivatives thereof as a depigmenting agent
The use of DHEA or at least one of its biological precursors or of its metabolic derivatives in or for the manufacture of a composition for topical application to the skin, as a pigmentation...
|
|
|
7345035 |
Treatment of osteoporosis and autoimmune disease with astrogorgiadiol
The invention provides methods of downregulating mRNA encoding osteopontin comprising administering to a cell or mammal an amount of astrogorgiadiol effective to downregulate production of mRNA...
|
|
|
7342004 |
Thioether sulphamate steroids as steroid inhibitors and anti-cancer compounds
There is provided use of a compound of Formula XI:
wherein R 3 is a sulphamate group and at least of R 1 or R 2 is a thioether group as disclosed by the present specification, capable of...
|
|
|
7320969 |
Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several...
|
|
|
7312207 |
Topical steroid cream formulations
Disclosed is a novel mometasone furoate cream formulation for topical administration in a oleaginous base containing propylene glycol. This cream is a cosmetically elegant preparation of mometasone...
|
|
|
7297688 |
Starter kit for low dose oral contraceptives
The present invention provides a contraceptive kit which helps to overcome or ameliorate the problem of breakthrough bleeding and spotting associated with lowest dose (15-20 ug EE) estrogen...
|
|
|
RE39861 |
Methods of extended use oral contraception
A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to...
|
|
|
7256185 |
Control of selective estrogen receptor modulators
The treatment of an estrogen sensitive condition by the administration of a selective estrogen receptor modulator is improved by additionally administering a progestationally active compound to the...
|
|
|
7241753 |
Method of treatment of prostate cancer
The present invention relates to the field of cancer, and in particular hormone dependent cancers including, but not limited to prostate, breast, endometrial, ovarian, thyroid, bone, and testis....
|
|
|
7235540 |
Methods of using 2-methoxyestradiol of high purity
2-methoxyestradiol having greater than 98% purity is obtained by synthetic or purification methods. This highly pure 2-methoxy estradiol, lacking estrogenic components, is particularly suitable for...
|
|
|
7235539 |
6-Hydroxyequilenins as estrogenic agents
This invention provides estrogen receptor modulators of formula I, having the structure
wherein,
R 1 is hydrogen, alkyl of 1–6 carbon atoms, benzyl, alkylcarbonyl of 2–7 carbon...
|
|
|
RE39678 |
Meiosis regulating compounds
Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.
|